A 17-year-old boy sought endocrine advice for an unusual gynecomastia that inexplicably recurred whenever he was treated with prednisone. This began at the age of 14, when the patient was diagnosed as having Addison's disease and was first treated with prednisone. An ensuing breast enlargement caused him to stop the medication and a regression of the gynecomastia was observed. Breast enlargement reappeared each time prednisone treatment resumed. Review of this problem led to the final diagnosis of congenital adrenal hyperplasia in a teenager who was genetically female but phenotypically male. 
THE CASE
A 17-year-old boy sought endocrinology consultation for a recurring gynecomastia. His parents were cousins and of very low income. He had been irregularly taking 0.1 mg fludrocortisone twice daily since early childhood when he had bouts of vomiting with hyponatremia and hyperkalemia of undetermined etiology. Three years before, he visited a physician for short stature (height, 144 cm). He had been the tallest among classmates while in primary school but later stopped growing, fell behind and finally was the shortest in high school. At the age of 14 years, radiography revealed advanced bone age (Ͼ19 years) with closed epiphyses. Then his serum testosterone and luteinizing hormone (LH) levels were in the adult range (21.8 nmol/L [normal, 9.36 -37.1 nmol/L] and 2.2 U/L [normal, 2-12 U/L], respectively). On the basis of cutaneous hyperpigmentation and the paraclinical findings of high plasma adrenocorticotropic hormone (ACTH) (440 [normal, 1.3-16 .7] pmol/L) and borderline low serum cortisol levels (149 nmol/L [normal, 138 -690 nmol/L]), he was diagnosed as having Addison's disease, and prednisone, 7.5 mg daily, was added to his medication. Later on, the patient developed gynecomastia, which worried him to the point that he tapered and stopped taking prednisone, to which the breast enlargement regressed after several months. After a resumption of prednisone, as advised by his primary physician, gynecomastia reappeared with a decreasing facial hair growth and evident lessening of the skin hyperpigmentation. In a workup for gynecomastia at this point, the serum estradiol and LH levels were elevated (276 [normal, Ͻ74] pmol/L and 14 U/L [normal, 2-12 U/L], respectively) and serum testosterone had decreased to lower than normal (3.22 nmol/L [normal, 9.36 -37.1 nmol/L]). Serum ␤-hCG was normal (0.01 [normal, Ͻ5 IU/mL]). He had not used any exogenous estrogens in any form. Scrotal sonography disclosed the intrascrotal absence of testes. Magnetic resonance imaging of the abdomen and pelvis revealed bilateral adrenal hyperplasia and the presence of small uterus and ovaries. When the patient had once again stopped taking prednisone, there was again a waning of gynecomastia and a waxing of skin hyperpigmentation, and laboratory studies disclosed a reversal of estradiol-to-testosterone ratio with serum levels in the ranges of a normal adult male (estradiol, 64.5 pmol/L and testosterone, 22.6 nmol/L). A serum dihydrotestosterone was near the upper limit of a normal adult male . Buccal smear was positive for Barr bodies, and karyotype was 46,XX. Treatment with prednisone was resumed, and testosterone enanthate was added to the therapeutic regimen. The dosage of testosterone enanthate was adjusted to keep LH levels in the lower limit of the normal range for an adult man. The patient was satisfied with this therapy, with no bothersome breast enlargement persisting and with a noticeable decrease in skin pigmentation. He was scheduled for removal of all internal sex organs and implantation of prosthetic testicles.
DISCUSSION
This patient is a unique case of congenital adrenal hyperplasia, an adrenal 21-hydroxylase deficiency, which had caused a huge penis-sized clitromegaly and a scrotumlike fusion of labia majora during her intrauterine life. 1,2 At birth, the apparently unambiguous, male external genitalia had caused her to be labeled male and to be consequently raised as a boy. Hypersecretion of ACTH resulted in skin hyperpigmentation, [2] [3] [4] and overproduction of androgens caused statural overgrowth in early childhood with premature fusion of epiphyses and the resultant short stature later on. 1 At the age of 14 years, when prednisone was started, the plasma ACTH was lowered toward normal level through feedback mechanism; and adrenal overproduction of androgens began to decrease, allowing pituitary LH secretion. The LH effect on ovaries resulted in estrogen secretion and physiologic breast development in a female 5 and not gynecomastia in a male. 6 On each occasion that the patient stopped taking the prescribed glucocorticoid, the ACTH overproduction was resumed and the androgen pathway was once more overdriven. 1 The resulting increased androgens inhibited gonadotrope LH secretion and thus stopped normal ovarian estrogen production; therefore, there was a regression of breast development and no further feminine secondary sexual maturity. 5 When resumption of glucocorticoid was accompanied by testosterone treatment, not only the pituitary overproduction of ACTH but also the normal LH secretion was suppressed, and as a result, the normal ovarian function and consequently feminine secondary sex-ual characteristics (including breast development) were prevented. 5 
CONCLUSION
In brief, the patient is an absolutely unique case of congenital adrenal hyperplasia that manifests itself as prednisone-induced breast enlargement in an adolescent who is genetically female but phenotypically male.
